Abstract:BackgroundMicroglia are considered the resident immune cells of the central nervous system (CNS). In response to harmful stimuli, an inflammatory reaction ensues in which microglia are activated in a sequenced spectrum of pro- and antiinflammatory phenotypes that are akin to the well-characterized polarization states of peripheral macrophages. A “classically” activated M1 phenotype is known to eradicate toxicity. The transition to an “alternatively” activated M2 phenotype encompasses neuroprotection and repair. In recent years, inflammation has been considered an accompanying pathology in response to the accumulation of extracellular amyloid-β (Aβ) in Alzheimer’s disease (AD). This study aimed to drive an M2a-biased immune phenotype with IL-4 in vitro and in vivo and to determine the subsequent effects on microglial activation and Aβ pathology.MethodsIn vitro, exogenous IL-4 was applied to BV2 microglial cell cultures to evaluate the temporal progression of microglial responses. In vivo, intracranial injections of an adeno-associate-virus (AAV) viral vector were performed to assess long-term expression of IL-4 in the frontal cortex and hippocampus of Aβ-depositing, APP/PS1 transgenic mice. Quantitative real-time PCR was used to assess the fold change in expression of biomarkers representing each of the microglial phenotypes in both the animal tissue and the BV2 cells. ELISAs quantified IL-4 expression and Aβ levels. Histological staining permitted quantification of microglial and astrocytic activity.ResultsBoth in vitro and in vivo models showed an enhanced M2a phenotype, and the in vivo model revealed a trend toward a decreased trend in Aβ deposition.ConclusionsIn summary, this study offers insight into the therapeutic potential of microglial immune response in AD.

Inflammatory factors and amyloid β-induced microglial polarization promote inflammatory crosstalk with astrocytes

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Microglia Polarization in Alzheimer’s Disease: Mechanisms and a Potential Therapeutic Target

Microglial polarization: novel therapeutic mechanism against Alzheimer’s disease

Role of Pro-Inflammatory Cytokines Released from Microglia in Alzheimer's Disease.

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Role Of Pro-Inflammatory Cytokines Released From Microglia In Alzheimer'S Disease

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Aβ-mediated neurotoxicity: Microglia-mediated oxidative neurotoxicity

Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimer'S Disease

Microglia Polarization From M1 to M2 in Neurodegenerative Diseases

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

The effects and potential of microglial polarization and crosstalk with other cells of the central nervous system in the treatment of Alzheimer’s disease

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Microglial purinergic signaling in Alzheimer's disease

Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology

The Downregulation of ITGAX Exacerbates Amyloid-β Plaque Deposition in Alzheimer's Disease by Increasing Polarization of M1 Microglia

Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice

Aβ and Tau Regulate Microglia Metabolism Via Exosomes in Alzheimer’s Disease

Aβ Induces Neuroinflammation and Microglial M1 Polarization via cGAS-STING-IFITM3 Signaling Pathway in BV-2 Cells

Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis